TABLE 2.
Compound |
Anticonflict Effectsa |
Rest/Sleep Postureb |
Observable Ataxiab |
Operant Responding–Decreasea |
Moderate Sedationb |
Deep Sedationb |
---|---|---|---|---|---|---|
ED50, mg/kg, i.v. (S.E.M.) | ||||||
Alprazolam | 0.007 (0.002) | 0.028 (0.01) | 0.08 (0.03) | 0.27 (0.07) | 0.31 (0.02) | 0.59 (0.11) |
Diazepam | 0.11 (0.07) | 0.71 (0.33) | 1.6 (0.11) | 1.7 (0.79) | 1.8 (0.12) | 6.9 (0.91) |
Zolpidem | NE | NE | 1.1 (0.1) | 0.10 (0.03) | NE | 5.7 (0.67) |
HZ-166 | 0.80 (0.3) | 1.2 (0.15) | NE [30] | NE [30] | NE [30] | NE [30] |
MRK-696 | 0.18 (0.06) | 0.27 (0.13) | 0.61 (0.28) | NE [3.0] | NE [3.0] | NE [3.0] |
TPA-023B | 0.031 (0.014) | 0.014 (0.003) | NE [1.0] | NE [1.0] | NE [1.0] | NE [1.0] |
NE, no effect (maximum dose tested, mg/kg, i.v.).
Rowlett et al. (2006), Fischer et al. (2010); unpublished.
Present study.